Cargando…
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
Autores principales: | Mastorino, Luca, Roccuzzo, Gabriele, Dapavo, Paolo, Siliquini, Niccolò, Avallone, Gianluca, Rubatto, Marco, Merli, Martina, Agostini, Andrea, Ribero, Simone, Quaglino, Pietro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545173/ https://www.ncbi.nlm.nih.gov/pubmed/35141879 http://dx.doi.org/10.1111/bjd.21048 |
Ejemplares similares
-
Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?
por: Mastorino, Luca, et al.
Publicado: (2022) -
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022) -
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
por: MASTORINO, Luca, et al.
Publicado: (2022) -
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study
por: Mastorino, Luca, et al.
Publicado: (2022) -
Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)